Bionomics launches ovarian cancer trial
The trial will evaluate BNC105 in combination with current standard therapies carboplatin and gemcitabine. The study will be conducted by the Australian and New Zealand Gynaecological Oncology Group (ANZGOG) working with the National Health and Medical Research Council Clinical Trials Centre (NH&MRC CTC) in Australia and the Hoosier Oncology Group in the United States.
Bionomics CEO and Managing Director Dr Deborah Rathjen said, “The design of this clinical trial is based on robust preclinical data demonstrating synergy between BNC105 and platinum-based therapies in improving survival rates of animals with solid tumours”.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.